Floatz logo

TAMOXIFEN

Invasive Breast Carcinoma

University of California, San FranciscoSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
89/ 100

Competitive context

58 Active assets in the Invasive Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Letrozole
Emory University
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
FULVESTRANT
Massachusetts General Hospital
Phase 2BB
TRASTUZUMAB
Massachusetts General Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

TAMOXIFEN is also rated in:

estrogen-receptor positive breast cancerDormant
BBB
Indicative ·
77 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
75 / 100
View asset →
breast carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →